Form 4: MannKind Director Steven B. Binder Reports Stock Transactions Following RSU Vesting

Director Steven B. Binder reports acquisition and disposal of MannKind Corporation stock related to the vesting of restricted stock units and tax obligations.

Summary

• Steven B. Binder, a director of MannKind Corporation, reported transactions involving the company's common stock.
• On May 10, 2025, Binder acquired 105,600 shares of common stock at $0 due to the vesting of a previously reported restricted stock unit award.
• The vesting was contingent upon achieving performance objectives related to MannKind's stock price and total shareholder return (TSR).
• The performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares.
• On May 12, 2025, Binder disposed of 87,430 shares at $4.56 and 6,441 shares at $4.56 to cover exercise price or tax liability related to the vesting of restricted stock units.
• On May 13, 2025, Binder sold 80,144 shares at a weighted average price of $4.69, ranging from $4.65 to $4.81, under a Rule 10B5-1 plan.
• Binder also acquired 52,854 restricted stock units on May 14, 2025, which vest immediately but will be delivered upon separation of service from the board.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and related to compensation. The achievement of performance objectives is a positive, but the subsequent sales are a neutral event.

Positives

• The vesting of restricted stock units indicates that MannKind met certain performance objectives related to stock price and shareholder return.
• The performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares.

Negatives

• The disposal of shares to cover tax obligations and under a 10B5-1 plan could be perceived negatively, although it's a common practice.

Risks

• Sales of shares by insiders, even under pre-arranged plans, can sometimes create short-term downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs suggests continued alignment of management incentives with shareholder value.

Industry Context

Insider transactions are common in the pharmaceutical and biotechnology industries, often tied to equity compensation plans. The vesting of RSUs based on TSR performance is a typical incentive structure.

Comparison to Industry Standards

• Companies like Amgen, Biogen, and Gilead Sciences also utilize restricted stock units and performance-based equity awards to align executive compensation with shareholder returns.
• The vesting conditions based on TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index are a common benchmark in the industry.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate insiders to manage potential conflicts of interest when selling company stock.

Stakeholder Impact

• The vesting of RSUs and subsequent transactions may have a minor impact on shareholders due to potential short-term price fluctuations.
• The achievement of performance objectives benefits shareholders by aligning management incentives with company performance.

Key Dates

Keywords

MannKind, MNKD, Director, Steven B. Binder, Form 4, Restricted Stock Units, RSU, Stock Transactions, Rule 10b5-1, Vesting, TSR